GlassScriptPhysician profile
David A Henderson
NPI 1821065095
$9,969.88
in general payments reported to CMS, 2019-2025
32 companies · $759 in 2025
The $759 reported for 2025 was more than what 93% of Hospitalist providers received nationally (typical 2025 total: $85.87).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $663 · 2020: $878 · 2021: $1,698 · 2022: $1,989 · 2023: $2,019 · 2024: $1,963 · 2025: $759.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,742.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,741.66 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $1,125.72 | 2020-2024 | Xarelto |
| Novartis Pharmaceuticals Corporation | $1,075.06 | 2020-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $1,043.25 | 2019-2025 | Jardiance, Spiriva Respimat, Stiolto Respimat |
| Gilead Sciences, INC. | $1,022.75 | 2021-2025 | Veklury |
| Pfizer INC. | $685.01 | 2019-2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $667.17 | 2019-2025 | Xifaxan |
| Astrazeneca Pharmaceuticals LP | $480.25 | 2019-2025 | Farxiga, Lokelma, Fasenra |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $411.50 | 2019-2025 | Lifevest |
| Merck Sharp & Dohme LLC | $377.30 | 2019-2025 | Dificid, Zerbaxa, Verquvo |
| Alnylam Pharmaceuticals INC. | $359.21 | 2022-2024 | Givlaari |
| Boston Scientific Corporation | $328.52 | 2019-2025 | Watchman Flx, Watchman, Watchman Access System |
| Allergan, INC. | $315.46 | 2019-2022 | |
| Paratek Pharmaceuticals, INC. | $309.00 | 2019-2024 | Nuzyra |
| E.R. Squibb & Sons, L.L.C. | $271.07 | 2019-2024 | Camzyos, Eliquis |
| Philips North America LLC | $183.73 | 2021-2022 |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $167.80 | 2019-2024 | Ozempic, Rybelsus |
| Electromed, INC. | $156.05 | 2021-2025 | Smartvest |
| Melinta Therapeutics, LLC | $148.65 | 2019-2022 | |
| Alexion Pharmaceuticals, INC. | $148.11 | 2021-2025 | Ultomiris |
| Glaxosmithkline, LLC. | $130.70 | 2022-2025 | Trelegy Ellipta |
| Heron Therapeutics, INC. | $117.21 | 2025 | Zynrelef |
| Scpharmaceuticals INC. | $112.00 | 2024-2025 | |
| Abbvie INC. | $68.24 | 2021 | |
| Takeda Pharmaceuticals U.S.A., INC. | $53.32 | 2020-2021 | |
| Opsens INC. | $49.99 | 2019 | |
| Kestra Medical Technology Services, INC. | $38.29 | 2023-2024 | Assure Wcd |
| Inari Medical, INC. | $36.92 | 2023 | Ct Thrombectomy System Kit, Flowtriever Catheter, S |
| Abbott Laboratories | $23.79 | 2024 | Freestyle Libre 3 |
| Bioxcel Therapeutics, INC. | $17.03 | 2023 | Igalmi |
| Neurocrine Biosciences, INC. | $16.75 | 2023 | Ingrezza |
| Otsuka America Pharmaceutical, INC. | $15.90 | 2019 | |
| Shire North American Group INC | $14.13 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw David Henderson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.